(Z)-Ligustilide

Cat. No.: HY-N0401A


CAS No.: 81944-09-4Molecular Formula: $C_{12}H_{14}O_2$ Molecular Weight: 190.24Target: Bacterial

Pathway: Anti-infection

Storage: -20°C, protect from light, stored under nitrogen

* In solvent: -80°C, 6 months; -20°C, 1 month (protect from light, stored under

nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (525.65 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	5.2565 mL	26.2826 mL	52.5652 mL
	5 mM	1.0513 mL	5.2565 mL	10.5130 mL
	10 mM	0.5257 mL	2.6283 mL	5.2565 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (13.14 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline) Solubility: \geq 2.5 mg/mL (13.14 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (13.14 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

(Z)-Ligustilide is extracted from Ligusticum chuanxiong Hort, has antimicrobial and antifungal activity, exhibits an average antifungal score of $5.6^{[1]}$. (Z)-Ligustilide inhibits the expression of FATP5 and DGAT, inhibits fatty acid uptake and esterification in mice and has potential as therapeutics for nonalcoholic fatty liver disease (NAFLD) [2]. (Z)-Ligustilide is also able to reactivate ER α , has epigenetic regulation, and is used in the study of tamoxifen-resistant breast cancer^[3].

CUSTOMER VALIDATION

- Eur J Inflamm. 2020 Jun.
- Preprints. 2023 JUl 25.

See more customer validations on $\underline{www.MedChemExpress.com}$

REFERENCES

[1]. Lee W, et al. Z-ligustilide and n-Butylidenephthalide Isolated from the Aerial Parts of Angelica tenuissima Inhibit Lipid Accumulation In Vitro and In Vivo. Planta Med. 2019 Jul;85(9-10):719-728.

[2]. Rodrigues AMS, et al. The antifungal potential of (Z)-ligustilide and the protective effect of eugenol demonstrated by a chemometric approach. Sci Rep. 2019 Jun 19;9(1):8729. doi: 10.1038/s41598-019-45222-y

[3]. Ma H, et al. Z-ligustilide restores tamoxifen sensitivity of ERa negative breast cancer cells by reversing MTA1/IFI16/HDACs complex mediated epigenetic repression of ERa. Oncotarget. 2017 Apr 25;8(17):29328-29345.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA